{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"HR, decrease to <60"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"HR, change to normal or no change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"HR, increase to >100"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Temp, decrease to <=35"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}],"title":"Temp, change to normal or no change"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Temp, increase to >=38"}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"The following criteria was used to flag vital signs of potential clinical importance: change from Baseline in heart rate (decrease to \\<60 bpm and increase to \\>100 bpm) and change in temperature from Baseline(increase to \\>=38 or decrease to \\<=35 degrees celsius). Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.","groups":[{"description":"Participants with multiple myeloma were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle=21 days).","id":"OG000","title":"Part 2: GSK2857916 3.40 mg/kg (MM)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Part 2 MM Population","reportingStatus":"POSTED","timeFrame":"Baseline and Up to 24.2 months (maximum duration of follow-up from first dose to last contact or death)","title":"Number of Participants With Change From Baseline in Heart Rate and Temperature-Part 2 (MM)","type":"PRIMARY","unitOfMeasure":"Participants"}